Protecting now from what comes next

The outbreak of COVID-19 caught the world off guard and severely constrained people's ability to live their lives to the fullest. Responses have been non-personal and broad (such as social distancing) or focused medical approaches targeting specific strains (such as vaccines). And while these solutions are crucial and these vaccines were developed at unprecedented speed, all responses are reactive.

What the world needs is a proactive approach. Nature harbors millions of unknown viruses and with virus mutations in humans, new infections are a given. However, we don’t know which one will strike next. The current reactive approach does not prepare us for these future threats.

It’s time for a new approach.

divider-L-1

Love Hugs

divider-L_2

our new Approach

Leyden Labs’ proactive approach protects against a broad range of viruses

To protect from what comes next, we need to act proactively and be ready for a broad range of viruses. At Leyden Labs, we expand the armamentarium of available tools by developing our platform and products with three innovative concepts:

Targeting the commonalities of viruses

The millions of unknown viruses harbored in nature can be grouped in a few dozen of viral families. By targeting the commonalities of these families, we can develop protection against entire virus families at once, including the unknown variants. Our focus is on respiratory viruses like influenza and coronaviruses, which are most likely to cause pandemics because they are transmitted through the air.

Attacking viruses where they attack us

Through our platform, we are developing nasal sprays that provide immediate protection because they attack viruses where they attack us – in our nasal passages – keeping people safe from catching infections and preventing people from spreading them to others.

Providing protection independent of people’s immune system

Through our nasal sprays we deliver antibodies in the mucosa of the nasal passages that provide the user instant protection. It does not rely on the defense of a person’s own immune system and can therefore also effectively support population groups at risk, such as elderly and immunocompromised people.

Leyden Labs’ product candidates

We are working toward accessible, self-administrable products, so people can take control and live their lives to the fullest by protecting themselves against catching infections and preventing transmission to others. In January 2022, we announced that we have an exclusive license to develop and commercialize CR9114, a pan-influenza antibody protecting against influenza A and B. We are working hard to develop our PanFlu product candidate and advance it into the clinic.

divider-L-1

Love Sports

divider-L_2

our team

We challenge limits

The city of Leiden (The Netherlands) inspired our name. For centuries, Leiden is known for unconventional thinking, the freedom to express this openly and scientific breakthroughs such as the first publications of Galileo’s famous Discorsi.

Our team of energetic, experienced and curious people is ready to go beyond to accomplish our mission. We strive for a fantastic life for all people. We aim for the highest, think unconventionally and focus relentlessly on delivering the impossible. In our team trust, integrity and inclusiveness are a given.

Our team

Meet our fantastic team. Together, we work towards our mission of freeing you from viruses.

Koenraad Wiedhaup Founder and CEO at Leyden Labs

Koenraad Wiedhaup

Founder and Chief Executive Officer
 

Jaap Goudsmit Founder and Chief Scientific Officer at Leyden Labs

Jaap Goudsmit

Founder and Chief Scientific Officer

Ronald Brus Founder and Chief Business Officer at Leyden labs

Ronald Brus

Founder and Chief Growth Officer
 

LL-Suha

Suha Jhaveri

Chief Business Officer
 

LL-Marieke-2

Marieke van der Lans

Chief Financial Officer

LL-Sanne

Sanne Melles

Chief Operations Officer
 

LL-Xavier

Xavier Maes

General Counsel

00-LL-placeholder

Sagrario Arias Rivas

Research Partnerships

LL-Anna-2

Anna Beukenhorst

Scientific Data

LL-Allison

Allison Bhattacharya

Mucosal Platform Discovery

LL-Carolyn

Carolyn Boudreau

Mucosal Platform Discovery

LL-Vivianne-2

Vivian Bouwer

Facilities & Projects

LL-Marianne-Busch

Marianne Busch

Preclinical & CMC

00-LL-placeholder

Görkem Cemali

Preclinical & CMC

LL-Maria

María Ángeles Corral

Product Lead Discovery

LL-Justin

Justin Crawford

Mucosal Platform Discovery

LL-Meiling

Meiling Dai

Mucosal Platform Discovery

LL-Janine

Janine de Jong

Executive Support

LL-Babette-2

Babette de Jong

Preclinical & CMC

Dennis de Vlaam Head of Operations at Leyden Labs

Dennis de Vlaam 

Partnerships & Procurement

00-LL-placeholder

Alex Deuschel

Scientific Data

LL-Alexander

Alexander Dingenouts

IT

LL-Virginia

Virginia Fernández

Product Lead Discovery

LL-Stephanie

Stephanie Fischinger

Product Lead Discovery

00-LL-placeholder

Jacopo Frallicciardi

Scientific Data

00-LL-placeholder

Carola Franso

Preclinical & CMC

LL-Ilse

Ilse Haisma

Mucosal Platform Discovery

LL-Alex-H

Alex Henriquez

IT

LL-Hellen

Hellen Houlleberghs

Clinical & Epidemiology

LL-Javante

Javante Ishmael-Langham

Mucosal Platform Discovery

LL-Boris

Boris Juelg

Clinical & Epidemiology

LL-Jaco-2

Jaco Klap

Scientific Data

LL-Clarissa-1

Clarissa Koch

Mucosal Platform Discovery

LL-Martin-2

Martin Koldijk

Scientific Data

Wouter Koudstaal Discovery at Leyden Labs

Wouter Koudstaal

Product Lead Discovery

LL-Fergus

Fergus Manford

Legal & IP

LL-Maurice

Maurice Mannesse

Preclinical & CMC

LL-Ian

Ian McGuinness

Regulatory Affairs

LL-Stephan

Stephen Mc Nally

Quality

LL-Joana

Joana Mello

Mucosal Platform Discovery

00-LL-placeholder

Guissela Moreno

Finance & Control

LL-Amanda

Amanda Motto

Finance & Control

LL-Andrea

Andrea Pastini

Clinical & Epidemiology

LL-Keira

Keira Lee Rice

Scientific Data

LL-Felix

Félix Risco

Product Lead Discovery

LL-Gieta

Gieta Salikram

Executive Support

LL-Mike

Mike Shaw

Business Development

LL-Nuno

Nuno Silva

Product Lead Discovery

LL-Mihaela

Mihaela Solca

Preclinical & CMC

LL-Jos

Jos Vaessens

IT

LL-Lotte-2

Lotte van Alst

Finance & Control

LL-Anita

Anita van den Biggelaar

Clinical & Epidemiology

00-LL-placeholder

Menno van Lummel

Preclinical & CMC

LL-Rene-Verdonk

René Verdonk

Program Management

LL-Carla

Carla Vogelezang

Preclinical & CMC

LL-Lars-2

Lars von Oerthel

Preclinical & CMC

00-LL-placeholder

Marianne Wooning

Clinical & Epidemiology

Bertjan Ziere Pre-clinical Leyden Labs

Bertjan Ziere

Preclinical & CMC

00-LL-placeholder-1

You?

Click for our vacancies!

Our Supervisory Board

Dinko Valerio
Founder and Chair of the Supervisory Board

John Martin (In memoriam)
Former CEO Gilead Sciences

Onno van de Stolpe
Former CEO Galapagos. 

James Shannon
Former CMO GSK and Global Head of Development at Novartis

Richard Whitley
Professor in Pediatrics and Microbiology, Medicine and Neurosurgery at University of Alabama

David Schenkein
General Partner GV

Stephen Knight
President and Managing Partner F-Prime Capital

Eli Casdin
Chief Investment Officer and Founder

Our investors

We are working together with a strong syndicate of investors and ambassadors. Our investors are GV (formerly Google Ventures), F-Prime Capital, Casdin Capital, Byers Capital / Brook Byers, Softbank Vision Fund 2, Invus and Bluebird Ventures.

GV_logo
F-Prime
Casdin
buyers-capital-brook-byers
Softbank
Invus
bluebird-venture-1

our values

join our mission

Become part of our journey

At Leyden Labs, we want to free humanity from the burden of respiratory viruses to let people live life to the fullest. We are moving fast and growing quickly. Are you interested in contributing?

Partners

We work closely together with academics, commercial researchers and other commercial parties to further develop our business.

Institutions and Governments

We aim to prepare society for future pandemics and are keen to help governments and institutions do so.

Investors

We are open to discussions with interested investors.

People

We are growing quickly and always looking for the best people to work with.

divider-L-1

Love Life

divider-L_2
LL-Blue

Contact

Media inquiries

Stay updated

Leyden Laboratories B.V.

Leiden Laboratory
Galileiweg 8
2333 BD Leiden
The Netherlands


Leyden Laboratories Co.

Boston Laboratory
191 Dexter Avenue
Watertown
MA 02472
United States


Leyden Labs S.L.

Granada Office
Avda. del Conocimiento 41.A210
Centro de Empresas
Parque Tecnológico de la Salud
18016 Granada
Spain


© Leyden Labs, 2021  |  Privacy Policy  |  Design by Ape to Zebra

Back to top Arrow